Zimmer Biomet (ZBH) announced that it now anticipates repurchasing up to $1B of its common stock during fiscal year 2026, a $250M increase from the company’s prior assumption.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $92 from $98 at Truist
- Zimmer Biomet participates in a conference call with JPMorgan
- Zimmer Biomet: Hold Reiterated as Execution Risks, Salesforce Transition, and CFO Departure Offset Q1 Beat and Margin Upside
- Zimmer Biomet price target lowered to $95 from $100 at JPMorgan
- Zimmer Biomet price target lowered to $105 from $110 at Stifel